Remdesivir (Veklury) is authorized by Health Canada to treat patients with severe COVID-19 symptoms who have pneumonia and need extra oxygen to help them breathe. The drug is administered intravenously and is only to be used in health care facilities where patients can be closely monitored.

CADTH is convening an implementation panel of clinical specialists with experience in the treatment of patients with severe symptoms of COVID-19, as well as an ethicist, to help determine criteria for the use of remdesivir. The panel’s objective is to develop criteria that could help identify which patients would benefit most from treatment with this drug. This work is being undertaken to support future pandemic preparedness, where evidence-informed criteria may be useful to support decision-making.

Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.